Clinical Data Novartis reveals more data behind Pluvicto expansion bid PharmaphorumNovartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaphorum Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer. Oncology Read full story Post navigation Previous: Regeneron immunotherapy combo comes up short in melanoma trialNext: AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026